Collaborations are an important element in Citryll’s strategy to bring CIT-013 to clinical Proof of Concept and ultimately to patients. We explore the broader potential for clinical utility of mitigating dysregulated NET activity with academic collaborators and industry partners. Citryll has a proprietary toolbox to study NET biology and protein citrullination and their role in human pathologies. This toolbox enables us together with our academic and industry partners to study the role of NETs in human disease on the one hand and the medical utility of CIT-013 on the other hand.
We are keen to explore opportunities to collaborate and partner with companies whose expertise in relevant therapeutic areas and clinical development of therapeutic antibodies will aid us in the development of innovative medicines addressing true medical need.
Part of Citryll’s strategy is to collaborate with academic groups with a keen interest and/or track-record in NET biology and translational research and with proven experience in human explant and animal in vivo models for RA, SLE, Interstitial Lung Disease (ILD) and IPF, Asthma, vasculitis, cancer and Alzheimer’s disease.